News by Subject
News by Disease
News by Date
Post Your News
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
US & Canada
Post an Event
News | News By Subject | News by Disease |
News By Date | Search News
Roche NimbleGen, Inc Introduces Novel NGS Target Enrichment Solution For Methylation Assessment
1/31/2014 8:55:49 AM
Madison, WI, USA, January 31, 2014 / B3C newswire / - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced the launch of the SeqCap Epi Target Enrichment System for DNA methylation assessment at single-base resolution. This system includes both a fixed content epigenome-wide design and a full range of custom target offerings. This product line was designed to provide epigenetic researchers with next-generation tools to study DNA methylation with advantages in breadth, depth and throughput over other technologies currently available in the market.
DNA methylation has been shown to play an important role in a host of biological processes, including gene expression, dosage compensation, genome stability and more. Its involvement in cancer and many other diseases has been increasingly studied, in recent years. Current research tools either provide limited efficiency or introduce experimental biases for genome-wide or targeted applications. Based on the proprietary probe design and manufacturing technologies from NimbleGen, the SeqCap Epi System, which was developed through collaborations with a number of key opinion leaders in epigenetic research, is designed to dramatically increase efficiency and accuracy for broad discovery applications as well as focused DNA methylation studies.
“We realized the strategy underlying the NimbleGen technology could help overcome a number of challenges in DNA methylation analysis,” said Dr. John Greally, Director of Center for Epigenomics at Albert Einstein College of Medicine, who has been a key collaborator of NimbleGen’s. “The SeqCap Epi custom designs have allowed us to focus our sequencing in a way that is tailored to the cell type we're studying, using new information about regulatory landscapes from the ENCODE and Roadmap projects. This allows us to get the most out of our sequencing, getting us beyond the inflexible genomic survey approaches the field has used in recent years.”
Epigenetic modifications also affect plant and animal trait development with agricultural applications. “NimbleGen’s technology has unique advantages for targeted bisulfite sequencing beyond the human genome,” said Nathan Springer, PhD, Director of Microbial and Plant Genomics Institute at University of Minnesota, another key collaborator of NimbleGen’s, “which makes it suitable for significant efficiency improvement and cost reduction in agricultural genomic research.”
“We are very excited to introduce a novel system for epigenetic research, through encouraging collaborations with leading scientists in this field.” said Dr. Rebecca Selzer, President, Roche NimbleGen. “This is another success story where the research community is utilizing NimbleGen technologies for developing better tools aimed at more meaningful discovery.”
For more information about Roche NimbleGen, please visit www.nimblegen.com.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, infectious diseases, inflammation, metabolism and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2012 Roche had over 82,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 45.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
NIMBLEGEN and SEQCAP are trademarks of Roche.
For life science research only.
Not for use in diagnostic procedures.
All trademarks used or mentioned in this release are protected by law.
For further information please contact:
Phone: +1 317 847 5172
Email : firstname.lastname@example.org
Help employers find you! Check out all the jobs and post your resume.